SCOPOLAMINE HYDROBROMIDE

First marketed in 1899

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H21NO4.BrH.3H2O
Molecular Weight	438.311
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.Br.[H][C@@]12O[C@]1([H])[C@H]3C[C@H](C[C@@H]2N3C)OC(=O)[C@H](CO)C4=CC=CC=C4

InChI

InChIKey=LACQPOBCQQPVIT-SEYKEWMNSA-N

InChI=1S/C17H21NO4.BrH.3H2O/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10;;;;/h2-6,11-16,19H,7-9H2,1H3;1H;3*1H2/t11-,12-,13-,14+,15-,16+;;;;/m1..../s1

HIDE SMILES / InChI

Molecular Formula	C17H21NO4
Molecular Weight	303.3529
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16175141 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf

The alkaloid L-(-)-scopolamine [L-(-)-hyoscine], a belladonna alkaloid, competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects. Scopolamine acts: i) as a competitive inhibitor at postganglionic muscarinic receptor sites of the parasympathetic nervous system, and ii) on smooth muscles that respond to acetylcholine but lack cholinergic innervation. It has been suggested that scopolamine acts in the central nervous system (CNS) by blocking cholinergic transmission from the vestibular nuclei to higher centers in the CNS and from the reticular formation to the vomiting center. Scopolamine can inhibit the secretion of saliva and sweat, decrease gastrointestinal secretions and motility, cause drowsiness, dilate the pupils, increase heart rate, and depress motor function. Scopolamine is used for premedication in anesthesia and for the prevention of nausea and vomiting (post operative and associated with motion sickness).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 3 (5-HT3) receptor 60 Target ID: CHEMBL2094132 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27108935	Antagonist 2760		2.09 µM [IC50]
Muscarinic acetylcholine receptor 160 Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1727135 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf	Antagonist 2760

Conditions

Condition	Modality	Highest Phase	Product
Motion sickness 43 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf	Preventing	Approved 8360	TRANSDERM SCOP Approved Use Transderm Scōp is an anticholinergic agent indicated in adults for the prevention of nausea and vomiting associated with: Motion Sickness and Post Operative Nausea and Vomiting (PONV) Launch Date 3.15446395E11
Postoperative nausea and vomiting 29 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf	Preventing	Approved 8360	TRANSDERM SCOP Approved Use Transderm Scōp is an anticholinergic agent indicated in adults for the prevention of nausea and vomiting associated with: Motion Sickness and Post Operative Nausea and Vomiting (PONV) Launch Date 3.15446395E11
Depression 233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17015814 https://www.ncbi.nlm.nih.gov/pubmed/23334071	Primary	Phase IV 63	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
5 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf	1 mg single, topical dose: 1 mg route of administration: Topical experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
369 ng × min/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
9.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf	1 mg single, topical dose: 1 mg route of administration: Topical experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
68.7 min REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
70% REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years n = 12 Health Status: healthy Age Group: 21 - 47 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	Other AEs: Dizziness, Lightheadedness... Other AEs: Dizziness (3 patients) Lightheadedness (3 patients) Nasal burning (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
0.9 mg 2 times / day multiple, oral Highest studied dose Dose: 0.9 mg, 2 times / day Route: oral Route: multiple Dose: 0.9 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 21.4 years n = 35 Health Status: healthy Age Group: 21.4 years Sex: M Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	Other AEs: Blurred vision, Dizziness... Other AEs: Blurred vision Dizziness Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
6 ug/kg single, intravenous Dose: 6 ug/kg Route: intravenous Route: single Dose: 6 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 22.8 years n = 9 Health Status: healthy Age Group: 22.8 years Sex: M Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) n = 12 Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	Other AEs: Dizziness, Dry mouth... Other AEs: Dizziness (4 patients) Dry mouth (3 patients) Blurred vision (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
10 mg 3 times / day multiple, oral Overdose Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	unhealthy, 83 years n = 1 Health Status: unhealthy Age Group: 83 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	Other AEs: Consciousness abnormal, Hyperthermia... Other AEs: Consciousness abnormal (1 patient) Hyperthermia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/25395072
0.5 mg single, intravenous Dose: 0.5 mg Route: intravenous Route: single Dose: 0.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15792397	healthy, adult n = 6 Health Status: healthy Age Group: adult Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15792397	Sources: https://pubmed.ncbi.nlm.nih.gov/15792397

AEs

AE	Significance	Dose	Population
Nasal burning	1 patient	0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years n = 12 Health Status: healthy Age Group: 21 - 47 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
Dizziness	3 patients	0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years n = 12 Health Status: healthy Age Group: 21 - 47 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
Lightheadedness	3 patients	0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years n = 12 Health Status: healthy Age Group: 21 - 47 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
Blurred vision		0.9 mg 2 times / day multiple, oral Highest studied dose Dose: 0.9 mg, 2 times / day Route: oral Route: multiple Dose: 0.9 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 21.4 years n = 35 Health Status: healthy Age Group: 21.4 years Sex: M Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
Dizziness		0.9 mg 2 times / day multiple, oral Highest studied dose Dose: 0.9 mg, 2 times / day Route: oral Route: multiple Dose: 0.9 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 21.4 years n = 35 Health Status: healthy Age Group: 21.4 years Sex: M Population Size: 35 Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
Dry mouth	3 patients	1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) n = 12 Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
Blurred vision	4 patients	1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) n = 12 Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
Dizziness	4 patients	1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) n = 12 Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
Consciousness abnormal	1 patient	10 mg 3 times / day multiple, oral Overdose Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	unhealthy, 83 years n = 1 Health Status: unhealthy Age Group: 83 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25395072
Hyperthermia	1 patient	10 mg 3 times / day multiple, oral Overdose Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	unhealthy, 83 years n = 1 Health Status: unhealthy Age Group: 83 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25395072

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 768 inhibitor 1579	inhibitor 1752	inhibitor 1837

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509 CYP2C8 901 CYP2C19 1463 OCT1 506 OCT2 638 OCT3 149 MATE1 304 MATE2 261	CYP3A 189	CYP1A2 689

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1673	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2C8 955	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP3A4 1909	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP3A4 1909	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
MATE1 306	inhibitor 3240 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 119.2 uM]
OCT3 149	inhibitor 3240 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 217.9 uM]
OCT2 639	inhibitor 3240 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 540.8 uM]
OCT1 523	inhibitor 3240 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 6.7 uM]
MATE2 261	inhibitor 3240 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 699.9 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A 189	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/16175141/	yes		yes (co-administration study) Comment: The AUC0–24h values of scopolamine were higher during the grapefruit juice period. They reached approximately 142% of the values associated with the control group (water period; P . 0.005) Sources: https://pubmed.ncbi.nlm.nih.gov/16175141/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:16794	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16794
MolPort	MolPort-005-938-576	https://www.molport.com/shop/molecule-link/MolPort-005-938-576
ZINC	ZINC000100037020	http://zinc15.docking.org/substances/ZINC000100037020

PubMed

Title	Date	PubMed
Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.	1976 Aug	10058
Behavioral studies of the effects of moderate oligemic hypoxia caused by bilateral clamping of carotid arteries in mice. Impairment of spatial working memory.	1998 Jul-Oct	10091712
Korean red ginseng saponins with low ratios of protopanaxadiol and protopanaxatriol saponin improve scopolamine-induced learning disability and spatial working memory in mice.	1999 Aug	10433468
Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice.	1999 Jun	10401555
American ginseng extract reduces scopolamine-induced amnesia in a spatial learning task.	1999 Nov	10586535
S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine.	1999 Nov	10578133
Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.	1999 Oct	11125734
Intra-medial prefrontal cortex injections of scopolamine increase instrumental responses for cocaine: an intravenous self-administration study in rats.	2000 Jan 15	10709961
Probing peripheral and central cholinergic system responses.	2000 Sep	11022397
Effects of MDL 73005 on water-maze performances and locomotor activity in scopolamine-treated rats.	2001 Apr	11526961
Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists.	2001 Apr	11495349
Male-female differences in rat hypothalamic-pituitary-adrenal axis responses to nicotine stimulation.	2001 Apr	11403996
The anti-amnesic effects of sigma1 (sigma1) receptor agonists confirmed by in vivo antisense strategy in the mouse.	2001 Apr 13	11292454
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism.	2001 Apr 27	11392629
Antimuscarinic treatment for lung diseases from research to clinical practice.	2001 Apr 27	11392626
Ultrasonic vocalizations as an index of social memory in female mice.	2001 Aug	11508722
Long-lasting cholinergic modulation underlies rule learning in rats.	2001 Feb 15	11160410
Sexual diergism in rat hypothalamic-pituitary-adrenal axis responses to cholinergic stimulation and antagonism.	2001 Jan 1	11226719
Scopolamine fails to diminish chronic haloperidol-induced purposeless chewing in rats.	2001 Jan 1	11205418
Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation.	2001 Jan 8	11163639
The effects of scopolamine on the spatial organization of cortical potentials in the rat brain.	2001 Jan-Feb	11265815
Occurrence of cadaverine in hairy roots of Brugmansia candida.	2001 Jul	11397445
Anti-ischemic and cognition-enhancing properties of NNC-711, a gamma-aminobutyric acid reuptake inhibitor.	2001 Jul 13	11470258
Drug-induced variations in the probability of occurrence of multiple corrective saccades.	2001 Jun	11453194
Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum.	2001 Jun	11399661
Dose- and time-dependent scopolamine-induced recovery of an inhibitory avoidance response after its extinction in rats.	2001 Jun	11275294
Could the 5-HT1B receptor inverse agonism affect learning consolidation?	2001 Mar	11323083
Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats.	2001 Mar	11274994
Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies.	2001 Mar	11181892
Memory impairment induced by cholinergic antagonists injected into the mushroom bodies of the honeybee.	2001 May	11467497
The role of muscarinic cholinoceptors in the retrieval of an operant food-related conditioned reflex in cats.	2001 May-Jun	11430573
Antihyperalgesic effects of the muscarinic receptor ligand vedaclidine in models involving central sensitization in rats.	2001 Sep	11514081

Patents

Sample Use Guides

In Vivo Use Guide

Transderm Scōp (scopolamine) transdermal system patch. Each Transderm Scōp patch is formulated to deliver in-vivo approximately 1 mg of scopolamine over 3 days. Initiation of Therapy Motion Sickness To prevent the nausea and vomiting associated with motion sickness, one Transderm Scōp patch (formulated to deliver approximately 1 mg of scopolamine over 3 days) should be applied to the hairless area behind one ear at least 4 hours before the antiemetic effect is required. Post Operative Nausea and Vomiting To prevent post operative nausea and vomiting, one Transderm Scōp patch should be applied the evening before scheduled surgery, except for caesarian section. For caesarian section surgery, to minimize exposure of the newborn baby to the drug, apply the patch one hour prior to caesarian section. Continuation of Therapy Should the patch become displaced, it should be discarded, and a fresh one placed on the hairless area behind the other ear. Motion Sickness If therapy is required for longer than 3 days, the first patch should be removed and a fresh one placed on the hairless area behind the other ear. Post Operative Nausea and Vomiting For perioperative use, the patch should be kept in place for 24 hours following surgery at which time it should be removed and discarded.

Route of Administration: Transdermal

In Vitro Use Guide

Rosmarinic acid treatment increases the expression of BDNF and GluR-2 proteins and prevents cell death of scopolamine-exposed (300 μM) organotypic hippocampal slice cultures.

Substance Class	Chemical Created by `admin` on `Thu Jul 06 00:40:58 UTC 2023` Edited by `admin` on `Thu Jul 06 00:40:58 UTC 2023`
Record UNII	451IFR0GXB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SCOPOLAMINE HYDROBROMIDE

Common Name

English

Hyoscine hydrobromide trihydrate [WHO-DD]

Common Name

English

HYOSCINE HYDROBROMIDE [VANDF]

Common Name

English

SCOPOLAMINUM HYDROBROMIDUM [HPUS]

Common Name

English

HYOSCINE HYDROBROMIDE

Common Name

English

SCOPOLAMINE HBR

Common Name

English

HYOSCINE HYDROBROMIDE TRIHYDRATE

Common Name

English

BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-, (1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, HYDROBROMIDE, HYDRATE (1:1:3), (.ALPHA.S)-

Systematic Name

English

6.BETA.,7.BETA.-EPOXY-1.ALPHA.H,5.ALPHA.H-TROPAN-3.ALPHA.-OL (-)-TROPATE (ESTER) HYDROBROMIDE TRIHYDRATE

Common Name

English

SCOPOLAMINE HYDROBROMIDE, TRIHYDRATE

Common Name

English

SCOPOLAMINE HYDROBROMIDE TRIHYDRATE [MI]

Common Name

English

SCOPOLAMINE HYDROBROMIDE HYDRATE

Common Name

English

HYOSCINE HBR

Common Name

English

SCOPOLAMINE HYDROBROMIDE [VANDF]

Common Name

English

SCOPOLAMINE HBR, TRIHYDRATE

Common Name

English

SCOPOLAMINE HYDROBROMIDE [USP-RS]

Common Name

English

SCOPOLAMINUM HYDROBROMIDUM

Common Name

English

NSC-757314

Code

English

SCOPOLAMINE HYDROBROMIDE HYDRATE [JAN]

Common Name

English

(-)-SCOPOLAMINE HYDROBROMIDE TRIHYDRATE

Common Name

English

SCOPOLAMINE HYDROBROMIDE TRIHYDRATE

Common Name

English

ISOPTO HYOSCINE

Brand Name

English

SCOPOLAMINE HYDROBROMIDE [USP MONOGRAPH]

Common Name

English

TRANSDERM-SCOP

Brand Name

English

HYOSCINE HYDROBROMIDE [EP MONOGRAPH]

Common Name

English

HYOSCINE HYDROBROMIDE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29704